The global needle-free drug delivery technology market size reached US$ 4.18 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.72 Billion by 2028, exhibiting a growth rate (CAGR) of 5.22% during 2023-2028. The escalating prevalence of chronic diseases, the increasing geriatric population, and the recent development of laser-powered needle-free injection technology (NFIT) represent some of the key factors driving the market.
Needle-free drug delivery technology refers to a method of administering medications to patients without using traditional needles. It includes micronozzle jet injectors, transdermal patches, inhalers, disposable cartridge injectors, nasal sprays, and ultrasound waves. They are widely used for vaccinations, insulin delivery, pain management, hormone therapy, and treating allergies, cancer, respiratory conditions, and other chronic diseases. As compared to traditional needle-based delivery systems, needle-free drug delivery technology reduces pain, minimizes discomfort and anxiety, enhances convenience, improves patient compliance, allows dosage customization, and prevents the risk of injuries and infections. It also offers faster medication delivery and aids in enhancing drug absorption, minimizing complications, and increasing treatment effectiveness. Needle-free drug delivery technology is also eco-friendly as it minimizes hazardous waste generation, reduces manufacturing emissions, and eliminates the need for product disposal.
Needle-free Drug Delivery Technology Market Trends:
The escalating prevalence of chronic diseases, such as diabetes, cancer, Crohn’s disease, multiple sclerosis, arthritis, osteoporosis, and cardiovascular diseases (CVDs), is one of the primary factors driving the market growth. Needle-free drug delivery technology is widely used to deliver insulin and medications to chronic disease patients without pain and discomfort, which improves treatment outcomes, reduces the risk of infections, and enhances patients’ quality of life. Furthermore, the widespread technology adoption to improve medication adherence, increase drug absorption, enhance treatment effectiveness, and minimize complications associated with needles is acting as another growth-inducing factor. Additionally, the recent development of a laser-powered needle-free injection technology (NFIT), which utilizes a laser-based system to blast microscopic jets of drugs into the skin with high precision, is positively influencing the market growth. Moreover, increasing technology utilization in veterinary care to administer vaccines, medications, and anesthesia to animals in a humane and stress-free manner is favoring the market growth. Apart from this, the implementation of various government initiatives to promote the adoption of needle-free drug delivery systems and support the development of advanced technologies are creating a positive outlook for the market growth. Other factors, including rising demand for vaccines due to the increasing prevalence of infectious diseases, increasing geriatric population, significant growth in the healthcare industry, extensive research and development (R&D) activities, and growing consumer awareness regarding the benefits of needle-free drug delivery technology, are anticipated to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global needle-free drug delivery technology market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on product, application, and end user.
- Jet Injector
- Novel Needles
- Transdermal Patch
The report has provided a detailed breakup and analysis of the needle-free drug delivery technology market based on the product. This includes inhaler, jet injector, novel needles, transdermal patch, and others.
- Vaccine Delivery
- Pain Management
- Insulin Delivery
A detailed breakup and analysis of the needle-free drug delivery technology market based on the application has also been provided in the report. This includes vaccine delivery, pain management, insulin delivery, and others.
End User Insights:
- Hospitals and Clinics
- Homecare Settings
- Research Laboratories
A detailed breakup and analysis of the needle-free drug delivery technology market based on the end user has also been provided in the report. This includes hospitals and clinics, homecare settings, research laboratories, academics, and others.
- North America
- United Kingdom
- Asia Pacific
- South Korea
- Latin America
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for needle-free drug delivery technology. Some of the factors driving the North America needle-free drug delivery technology market included the increasing prevalence of chronic diseases, the implementation of various government initiatives, and rapid technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global needle-free drug delivery technology market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Akra Dermojet, Antares Pharma Inc. (Halozyme Therapeutics Inc.), Crossject, Mika Medical Co., PharmaJet, Portal Instruments Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
|Base Year of the Analysis
||Inhaler, Jet Injector, Novel Needles, Transdermal Patch, Others
||Vaccine Delivery, Pain Management, Insulin Delivery, Others
|End Users Covered
||Hospitals and Clinics, Homecare Settings, Research Laboratories, Academics, Others
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Akra Dermojet, Antares Pharma Inc. (Halozyme Therapeutics Inc.), Crossject, Mika Medical Co., PharmaJet, Portal Instruments Inc., etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Benefits for Stakeholders:
- IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the needle-free drug delivery technology market from 2017-2028.
- The research study provides the latest information on the market drivers, challenges, and opportunities in the global needle-free drug delivery technology market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the needle-free drug delivery technology industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.